Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors.

Yan, Marie; Hernandez, Alejandro; Chan, Kelvin K; Stanbrook, Matthew B; Blanchette, Phillip S; Johnston, James C; Lee, Samantha M; Macdonald, Liane et al. · Clin Infect Dis · 2025

case_control · Level III

Where this comes from

Abstract

In this population-based study, we examined the risk of nontuberculous mycobacterial disease associated with immune checkpoint inhibitors among people with cancer. Using a nested case-control design, we identified 184 cases and 714 matched controls; there was no significant association on conditional logistic regression (adjusted odds ratio, 0.51 [95% confidence interval, .17-1.50]; P = .22).

Medical subject headings